272 related articles for article (PubMed ID: 24156782)
1. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
[TBL] [Abstract][Full Text] [Related]
2. CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma.
Lun SW; Cheung ST; Cheung PF; To KF; Woo JK; Choy KW; Chow C; Cheung CC; Chung GT; Cheng AS; Ko CW; Tsao SW; Busson P; Ng MH; Lo KW
PLoS One; 2012; 7(12):e52426. PubMed ID: 23285037
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.
Chan KC; Chan LS; Ip JC; Lo C; Yip TT; Ngan RK; Wong RN; Lo KW; Ng WT; Lee AW; Tsao GS; Kahn M; Lung ML; Mak NK
Sci Rep; 2015 Apr; 5():9979. PubMed ID: 25897700
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-183 suppresses cancer stem-like cell properties in EBV-associated nasopharyngeal carcinoma.
Cheung CC; Lun SW; Chung GT; Chow C; Lo C; Choy KW; Lo KW
BMC Cancer; 2016 Jul; 16():495. PubMed ID: 27431799
[TBL] [Abstract][Full Text] [Related]
5. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
[No Abstract] [Full Text] [Related]
6. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
Naz S; Leiker AJ; Choudhuri R; Preston O; Sowers AL; Gohain S; Gamson J; Mathias A; Van Waes C; Cook JA; Mitchell JB
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1295-1305. PubMed ID: 33838214
[TBL] [Abstract][Full Text] [Related]
8. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
Graham B; Curry J; Smyth T; Fazal L; Feltell R; Harada I; Coyle J; Williams B; Reule M; Angove H; Cross DM; Lyons J; Wallis NG; Thompson NT
Cancer Sci; 2012 Mar; 103(3):522-7. PubMed ID: 22181674
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.
Spiegelberg D; Mortensen AC; Selvaraju RK; Eriksson O; Stenerlöw B; Nestor M
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):974-982. PubMed ID: 26627081
[TBL] [Abstract][Full Text] [Related]
10. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
11. Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis.
Chen L; Chan LS; Lung HL; Yip TTC; Ngan RKC; Wong JWC; Lo KW; Ng WT; Lee AWM; Tsao GSW; Lung ML; Mak NK
Phytomedicine; 2019 Oct; 63():153058. PubMed ID: 31394414
[TBL] [Abstract][Full Text] [Related]
12. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.
Spiegelberg D; Dascalu A; Mortensen AC; Abramenkovs A; Kuku G; Nestor M; Stenerlöw B
Oncotarget; 2015 Nov; 6(34):35652-66. PubMed ID: 26452257
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
Kang MH; Reynolds CP; Houghton PJ; Alexander D; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Maris JM; Wozniak A; Smith MA
Pediatr Blood Cancer; 2012 Jul; 59(1):185-8. PubMed ID: 21538821
[TBL] [Abstract][Full Text] [Related]
14. FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition.
Ye M; Huang W; Wu WW; Liu Y; Ye SN; Xu JH
Oncotarget; 2017 Feb; 8(9):15364-15376. PubMed ID: 28157708
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
Ma L; Zhang G; Miao XB; Deng XB; Wu Y; Liu Y; Jin ZR; Li XQ; Liu QZ; Sun DX; Testa JR; Yao KT; Xiao GH
FEBS J; 2013 May; 280(9):2027-41. PubMed ID: 23461856
[TBL] [Abstract][Full Text] [Related]
16. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
17. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.
Chiu SH; Wu CC; Fang CY; Yu SL; Hsu HY; Chow YH; Chen JY
Oncotarget; 2014 Sep; 5(18):8583-601. PubMed ID: 25261366
[TBL] [Abstract][Full Text] [Related]
19. BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc.
Li N; Yang L; Qi XK; Lin YX; Xie X; He GP; Feng QS; Liu LR; Xie X; Zeng YX; Feng L
Cell Death Dis; 2018 Jul; 9(7):761. PubMed ID: 29988031
[TBL] [Abstract][Full Text] [Related]
20. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells.
Mei YP; Zhou JM; Wang Y; Huang H; Deng R; Feng GK; Zeng YX; Zhu XF
Cell Cycle; 2007 Jun; 6(11):1379-85. PubMed ID: 17507800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
